Authors (year) | Type of study (country) | Study population (type) | Age (mean) | Sample size (N) | HBV prevalence N (%) | HCV prevalence N (%) | Number (type of laboratory test) |
---|---|---|---|---|---|---|---|
Johnston et al. [16] | Cross-sectional (Dominican Republic) | LGBT | ≥ 15 | 1388 | 28 (2.05%) | 53 (3.85%) | HBV: HBsAg BIO-CARD HCV: Bioblot HCV |
Gutierrez et al. [17] | Cross-sectional (Spain) | LGBT | 18–41 | 762 | 27 (3.5%) | 6 (0.8%) | HBV: microparticle Enzyme Immunoassay HCV: ELISA, line immunoassay |
Carobene et al. [2] | Cross-sectional (Argentina) | TGs (Both) | 29 | 273 | 106 (40%) | 12 (4.5%) | ELISA, particle Agglutination |
Luzzati et al. [18] | Retrospective (Italy) | TGs (Both) | 33.5 ± 7.7 | 243 (MTF: 218 FTM: 25) | MTF: 10 (4.6%) FTM: 2 (4%) | MTF: 8 (3.5%) FTM: 2 (8%) | HBV: immunoassays Enzygnost, Chemiluminescent microparticle Immunoassay, CMIA HCV: immunoassay Ortho HCV 3.0 Elisa Test System, immunoblotting Chiron Riba HCV 3.0 SIA |
Ahsan et al. [19] | Retrospective (Pakistan) | TGs (both) | All ages | 877 | NR | 128 (14.6%) | HCV: RAPID ICT test, ELISA |
Brito et al. [20] | Cross-sectional (Dominican Republic) | MTF | ≥ 18 | 100 | 4 (4%) | 1 (1%) | HBV: hepatitis B surface antigen (HBsAg II, COBAS, Roche Diagnostics) HCV: hepatitis C antibody (anti-HCV II, COBAS, Roche Diagnostics) |
Krieger et al. [21] | Retrospective (USA) | TGs (Both) | 35.5–41.3 | 1005 | 48 (4.8%) | NR | HBV serology (surface antigen and antibody) |
Facente et al. [22] | Cross-sectional (USA) | MTF | > 30 | 951 | NR | 236 (24.8%) | HCV: ELISA |
Adeyemi et al. [23] | Cross-sectional (Nigeria) | MTF | 25 | 717 | 69 (10%) | NR | HBV serology (surface antigen and antibody) |
Hadikusumo et al. [24] | Cross-sectional (Indonesia) | TGs (Both) | 19–60 | 107 | 10 (9.3%) | 7 (6.5%) | HBV: reverse passive hemagglutination assay, PCR HCV: reverse particle hemagglutination method, PCR |